PORTLAND, IA, UNITED STATES, January 28, 2025 /⁨EINPresswire.com⁩/ -- According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% …

… collaboration is expected to strengthen Biocon Biologics’ foothold in the Japanese … markets globally. The approval follows Biocon Biologics’ settlement and licensing agreement … biosimilars. Ustekinumab is a monoclonal antibody targeting interleukin-12 (IL-12 …

… Yoshindo Inc. Ustekinumab, a monoclonal antibody, is approved for the treatment … and Psoriatic Arthritis (PsA). Biocon Biologics previously notified the stock … and Drug Administration (USFDA) granted Biocon Biologics' Bengaluru facility “Voluntary …

Shares of Biocon surged 7.79 per cent … market. Ustekinumab is a monoclonal antibody indicated for the treatment of … ,” said the company spokesperson at Biocon Biologics. “This approval underscores our …

… monoclonal antibody for autoimmune conditions. The PMDA’s approval allows Biocon Biologics … markets globally. The approval follows Biocon Biologics’ settlement and licensing … biosimilars. Ustekinumab is a monoclonal antibody targeting interleukin-12 (IL-12 …

… NSE. Key Highlights: Regulatory Approval: Biocon Biologics received approval to market … . Global Collaboration: The approval follows Biocon Biologics’ licensing agreement with Janssen … Potential: Ustekinumab is a monoclonal antibody targeting IL-12 and IL …

… nephritis and severe asthma.  Biocon overview Biocon is a biopharmaceutical company. … biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin, and … Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka …

Biocon Executive Chairperson Kiran Mazumdar-Shaw … team reported that their "antibody treatment in mice is effective …

… consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make … Stelara (Ustekinumab). YESINTEK, a monoclonal antibody, is approved for the treatment … Colitis, Plaque Psoriasis, Psoriatic Arthritis Biocon Limited, publicly listed in 2004 …

… Segments Drug Class Monoclonal Antibodies Proteins Peptides Others Therapeutic … classes, such as monoclonal antibodies, proteins, peptides, and … Report include: Amgen BIOCAD Biocon Celltrion Coherus BioSciences Reddy… REST OF THE WORLD Biocon Dr. Reddy' …